The Leland Stanford Junior University, also known as Stanford University, has been awarded a $487,973 Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) to investigate key questions related to pre-leukemic hematopoietic stem cell (PHSC) clonal evolution, kinetics, and cell non-autonomous effects in the development of acute myeloid leukemia (AML). The research aims to provide novel insights into the genetic events and cellular kinetics that occur in the progression from pre-leukemia to de novo AML, with the goal of identifying the PHSC as a critical cellular target for the development of curative targeted therapies. This 5-year project, with an award date of January 1, 2025, builds upon previous genomic studies that have demonstrated the role of pre-leukemic mutations and clonal hematopoiesis in the pathogenesis of AML.
Generated 2/25/25, 4:53 AM